Publicacións nas que colabora con Juan Rafael Haba Rodríguez (14)

2024

  1. Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology

    Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 98-108

2022

  1. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

  2. SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 693-702

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

2020

  1. The economic burden of metastatic breast cancer in Spain

    European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24

2017

  1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

2016

  1. High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer

    Oncologist, Vol. 21, Núm. 2, pp. 150-155

2015

  1. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795

2014

  1. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: Results from the GEICAM/2006-14 trial

    British Journal of Cancer, Vol. 110, Núm. 5, pp. 1139-1147

2012

  1. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: Results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

    Annals of Oncology, Vol. 23, Núm. 12, pp. 3069-3074

2011

  1. Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer

    Breast Cancer Research and Treatment, Vol. 125, Núm. 1, pp. 273-278

2009

  1. Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial

    Breast Cancer Research and Treatment, Vol. 116, Núm. 2, pp. 351-358

2008

  1. Neoadjuvant endocrine therapy for breast cancer: Past, present and future

    Anti-Cancer Drugs, Vol. 19, Núm. 4, pp. 339-347

  2. Time-to-progression in breast cancer: A stratification model for clinical trials

    Breast, Vol. 17, Núm. 3, pp. 239-244